Genetic polymorphisms and bronchiolitis obliterans syndrome after lung transplantation: Promising results and recommendations for the future

Transplantation

Volumn 93, Issue 2, 2012, Pages 127-135

  Kastelijn, Elisabeth A ^a   Van Moorsel, Coline H M ^a,b   Ruven, Henk J T ^a   Lammers, Jan Willem J ^b   Grutters, Jan C ^a,b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bronchiolitis obliterans syndrome; Cytokine genes; Genetic polymorphisms; Innate immunity genes

Indexed keywords

BRONCHIOLITIS OBLITERANS SYNDROME; CD14 GENE; CHRONIC GRAFT REJECTION; FCGRIIA GENE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GRAFT RECIPIENT; HUMAN; IFNG GENE; IL10 GENE; IL1B GENE; IL1R1 GENE; IL1RN GENE; IL6 GENE; INNATE IMMUNITY; KIR GENE; LUNG DISEASE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MBL GENE; MMP7 GENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TGFB1 GENE; TLR4 GENE; TLR9 GENE; TNFA GENE;

BRONCHIOLITIS OBLITERANS; CYTOKINES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; INTERLEUKIN-6; LUNG TRANSPLANTATION; MALE; POLYMORPHISM, GENETIC; RISK FACTORS; SYNDROME; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84855858087     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823915d5     Document Type: Review

References (54)

1. Studer SM, Levy RD, McNeil K, et al. Lung transplant outcomes: A review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 2004; 24: 674.
2. Weigt SS, Wallace WD, Derhovanessian A, et al. Chronic allograft rejection: Epidemiology, diagnosis, pathogenesis, and treatment. Semin Respir Crit Care Med 2010; 31: 189.
3. Belperio JA, Weigt SS, Fishbein MC, et al. Chronic lung allograft rejection: Mechanisms and therapy. Proc Am Thorac Soc 2009; 6: 108.
4. Bowdish ME, Arcasoy SM, Wilt JS, et al. Surrogate markers and risk factors for chronic lung allograft dysfunction. Am J Transplant 2004; 4: 1171.
5. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
6. Knight JC. Regulatory polymorphisms underlying complex disease traits. J Mol Med (Berl) 2005; 83: 97.
7. Holweg CT, Weimar W, Uitterlinden AG, et al. Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. J Heart Lung Transplant 2004; 23: 1017.
8. Palmer SM, Klimecki W, Yu L, et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant 2007; 7: 693.
9. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant.AmJ Respir Crit Care Med 2005; 171: 780.
10. Snyder LD, Hartwig MG, Ganous T, et al. Cytokine gene polymorphisms are not associated with bronchiolitis obliterans syndrome or survival after lung transplant. J Heart Lung Transplant 2006; 25: 1330.
11. Lu KC, Jaramillo A, Lecha RL, et al. Interleukin-6 and interferongamma gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2002; 74: 1297.
12. Eskdale J, Gallagher G, Verweij CL, et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465.
13. Bouma G, Crusius JB, Oudkerk Pool M, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996; 43: 456.
14. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369.
15. Goldstein DR, Palmer SM. Role of Toll-like receptor-driven innate immunity in thoracic organ transplantation. J Heart Lung Transplant 2005; 24: 1721.
16. Jackson A, Palmer S, Davis RD, et al. Cytokine genotypes in kidney, heart, and lung recipients: Consequences for acute and chronic rejection. Transplant Proc 2001; 33: 489.
17. Vamvakopoulos JE, Taylor CJ, Green C, et al. Interleukin 1 and chronic rejection: Possible genetic links in human heart allografts. Am J Transplant 2002; 2: 76.
18. Awad M, Pravica V, Perrey C, et al. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999; 60: 343.
19. El-Gamel A, Awad MR, Hasleton PS, et al. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 1999; 18: 517.
20. Awad MR, El-Gamel A, Hasleton P, et al. Genotypic variation in the transforming growth factor-beta1 gene: Association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014.
21. Vamvakopoulos JE, Taylor CJ, Green C, et al. Genetic modulators of interleukin 1 activity influence the development of chronic rejection in human thoracic allografts. Transplant Proc 2001; 33: 1563.
22. Kastelijn EA, van Moorsel CH, Rijkers GT, et al. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 2010; 29: 665.
23. Munster JM, van der Bij W, Breukink MB, et al. Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation. Transplantation 2008; 86: 1857.
24. Kwakkel-van Erp JM, van de Graaf EA, Paantjens AW, et al. The killer immunoglobulin-like receptor (KIR) group A haplotype is associated with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2008; 27: 995.
25. Kastelijn EA, van Moorsel CH, Ruven HJ, et al. Genetic polymorphisms in MMP7 and reduced serum levels associate with the development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 680.
26. Pravica V, Perrey C, Stevens A, et al. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000; 61: 863.
27. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS):Anovel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735.
28. Verleden GM, Vos R, De Vleeschauwer SI, et al. Obliterative bronchiolitis following lung transplantation: From old to new concepts? Transpl Int 2009; 22: 771.
29. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832.
30. Verleden SE, Vos R, Mertens V, et al. Heterogeneity of chronic lung allograft dysfunction: Insights from protein expression in broncho alveolar lavage. J Heart Lung Transplant 2011; 30: 667.
31. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138: 1202.
32. Kleeberger W, Versmold A, Rothämel T, et al. Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury. Am J Pathol 2003; 162: 1487.
33. Pravica V, Asderakis A, Perrey C, et al. In vitro production of IFNgamma correlates with CA repeat polymorphism in the human IFNgamma gene. Eur J Immunogenet 1999; 26: 1.
34. Magnan A, Mege JL, Escallier JC, et al. Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med 1996; 153: 1431. (Pubitemid 126665771)
35. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199.
36. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185.
37. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002; 23: 301.
38. Garred P, Larsen F, Seyfarth J, et al. Mannose-binding lectin and its genetic variants. Genes Immun 2006; 7: 85.
39. Huard B, Karlsson L, Triebel F. KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation. Eur J Immunol 2001; 31: 1728.
40. Hsu KC, Liu XR, Selvakumar A, et al. Killer Ig-like receptor haplotype analysis by gene content: Evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002; 169: 5118.
41. Marsh SG, Parham P, Dupont B, et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Immunogenetics 2003; 55: 220.
42. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: An overview. Mol Cell Biochem 2003; 253: 269.
43. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168: 628.
44. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164.
45. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: Divide and conquer? J Heart Lung Transplant 2010; 29: 1358.
46. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010; 29: 531.
47. Banerjee B, Ling KM, Sutanto EN, et al. The airway epithelium is a direct source of matrix degrading enzymes in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2011; 30: 1175.
48. Riise GC, Ericson P, Bozinovski S, et al. Increased net gelatinase but not serine protease activity in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010; 29: 800.
49. Taghavi S, Krenn K, Jaksch P, et al. Broncho-alveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans. Am J Transplant 2005; 5: 1548.
50. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83: 150.
51. Bharat A, Fields RC, Steward N, et al. CD4 25 regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant 2006; 6: 1799.
52. Hodge G, Hodge S, Chambers D, et al. Bronchiolitis obliterans syndrome is associated with absence of suppression of peripheral blood Th1 proinflammatory cytokines. Transplantation 2009; 88: 211.
53. Cox ED, Hoffmann SC, DiMercurio BS, et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72: 720.
54. Hoffmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2: 560.